India’s Venus Remedies (NSE: VENUSREM) has won separate marketing authorizations for off-patent cancer drugs in the Philippines and Iraq.
The company, which is among the 10 leading fixed-dosage injectable manufacturers in the world, has secured marketing approval for bleomycin from the Philippines, the second largest market in the Association of Southeast Asian Nations (ASEAN) region, where the firm has a sizeable presence.
Venus has also entered the Iraq market for the first time, with a product registration for gemcitabine in the Middle Eastern country.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze